Impact of Health Insurance on Pharmaceutical Expenditures

In the past few decades, the landscape of healthcare has witnessed unprecedented changes, particularly regarding pharmaceutical expenditures. The interplay between health insurance coverage and pharmaceutical spending is critical for understanding this evolution.

The Rise of Pharmaceutical Spending

Pharmaceutical spending has outpaced other healthcare expenditures over the years. Between 1987 and 1996, the number of people with insurance coverage surged, contributing to an increased demand for medications. This increase in coverage played a pivotal role in driving pharmaceutical spending up, accounting for between one-fourth to one-half of the observed growth due to what is known as the moral hazard effect.

What is Moral Hazard?

Moral hazard refers to the tendency for individuals to take on more risk when they are insulated from the consequences. In the context of health insurance, it means that when individuals have insurance coverage, they are more likely to utilize medical services, including prescription drugs, as they do not bear the full cost. This phenomenon directly influences drug usage patterns and spending levels.

Technological Advancements and Their Role

The link between insurance and pharmaceutical expenditures is further compounded by technological advancements. The introduction of new drugs and therapies not only meets existing medical needs but also stimulates demand for insurance coverage. As innovative medications emerge, they often require patients to turn to insurance to manage costs.

Moreover, advancements in information technology have enabled the development of pharmacy benefit management (PBM) systems. These systems aim to reduce the real price of drug coverage. Consequently, the growth of insurance not only fosters a higher uptake of medications but also encourages pharmaceutical companies to invest in research and development (R&D) for new products.

The Tax Subsidy and Its Implications

The tax benefits associated with employer-sponsored insurance can prompt consumers to opt for more extensive insurance plans, which may, in turn, lead to excessive drug consumption and promotion. This inefficiency is not confined to pharmaceuticals but extends to all healthcare services, raising questions about the sustainability of rapid spending growth in the sector.

Indirect Effects of Insurance Growth

Beyond moral hazard, the growth in insurance coverage has indirect effects on drug spending. For instance, increased coverage may push pharmaceutical companies to ramp up direct-to-consumer (DTC) advertising. The relaxation of FDA regulations in 1997 allowed drug manufacturers to market their products more freely, likely increasing the demand for advertised medications. With insurance covering a significant portion of drug costs, consumer demand becomes less price-sensitive, further augmenting the potential profitability of these advertising campaigns.

Trends in Drug Spending

The analysis of spending trends over time indicates a shift in the dynamics of healthcare financing. Historically, drug spending grew at a slower pace compared to hospital expenditures. However, since the late 1980s, this trend has reversed, with drug spending outpacing hospital costs. This shift is indicative of changing consumer behavior, driven by increased insurance coverage that promotes greater access to medications.

Impact of Health Insurance on Pharmaceutical Expenditures

The 1990s were a turning point for American healthcare—not because of a deadly pandemic or a sweeping political reform, but due to something far more subtle: a skyrocketing surge in prescription drug spending. In a matter of years, medications that once made up a sliver of the national healthcare budget became one of its fastest-growing expenses.

Prescription Drug Spending: The Numbers Behind the Boom

In 1980, prescription drugs made up just 4.9% of total health expenditures in the U.S. By 1999, that share had grown to 8.5%. And while general healthcare costs rose at about 3.3% annually by the end of the decade, outpatient drug spending soared at 17% per year.

ALSO READ: Importance of Insurance for Production Loss in the Pharmaceutical Industry

The Role of Health Insurance: More Than Just Coverage

The key driver behind the surge was an under-the-radar transformation: a dramatic expansion in drug insurance coverage.

In the 1980s, insurance plans typically did not cover outpatient prescription drugs. Patients paid out of pocket for most medications. But by the 1990s, that changed rapidly.

According to Danzon and Pauly’s research:

• The share of drug spending paid out of pocket fell from 69.4% in 1980 to 33.4% in 1999
• Most of this change wasn’t because policies became more generous—but because more people got coverage

Between 1987 and 1996, the number of people with prescription drug insurance increased by 65%. And this coverage expansion unleashed what economists call “moral hazard”—when people consume more services simply because they’re insured.

Moral Hazard in Action: When Low Cost Means More

If you had to pay the full cost of a $200 prescription, you might think twice before filling it. But if your insurance covers 80% of it, you’re more likely to say yes.

That’s moral hazard, and it's not just a theory. The study estimates that this effect—people using more medications because they weren’t paying out of pocket—was responsible for 25% to 50% of the increase in drug spending during the 1990s.

Indirect Impact: More Insurance, More Innovation, More Ads

The growth of insurance coverage didn’t just change how people used drugs—it changed which drugs were developed, how they were marketed, and how the system worked.

Here’s how:

1. Incentives for New Drug Development

More insurance meant more demand. That made pharmaceutical companies more confident in investing billions into R&D for new therapies, especially for common, chronic conditions like:

• Depression
• High cholesterol
• Acid reflux

These were areas with large potential insured populations, making new product development far more appealing.

2. A Boom in Direct-to-Consumer Advertising

In 1997, the FDA relaxed rules for direct-to-consumer (DTC) drug ads, allowing companies to market medications on TV and in magazines more freely. Add in more insured consumers with lower out-of-pocket costs, and you’ve got a perfect storm.

• Insurance reduced consumer price sensitivity
• Lower price sensitivity made advertising more effective
• Drug companies ramped up their marketing budgets

From Hospital to Pharmacy: A Shift in How Care Was Delivered

The 1990s didn’t just bring more drugs—it brought a shift in how we think about healthcare.

Thanks to new medications and better outpatient coverage, care began to move from hospitals to homes. Chronic conditions that once required inpatient treatment could now be managed with a daily pill. That meant:

• Fewer hospital stays
• More prescriptions filled
• A greater share of national health spending devoted to medication

Insurance made these shifts affordable—for patients and providers alike.

How the U.S. Compared to the Rest of the World

Interestingly, other countries saw drug spending rise too—but not as fast.

In nations like Germany and the UK, where universal drug coverage was already in place, the spending increases were more modest. Why?

• They already had insurance in place, so there was less room for “moral hazard” to grow
• Their drug prices were more tightly regulated
• They didn’t experience the same explosion in consumer-targeted drug advertising

This comparison reinforces the idea that it was the growth in U.S. insurance coverage that set the country apart in pharmaceutical spending.

Conclusion

In summary, the relationship between health insurance and pharmaceutical expenditures is complex and multifaceted. The increase in insurance coverage has substantially driven the demand for pharmaceuticals, primarily through moral hazard effects. Technological advancements and tax incentives further shape this landscape, while regulatory changes impact how drugs are marketed and consumed.

As healthcare continues to evolve, understanding these dynamics will be crucial for policymakers and stakeholders aiming to ensure that spending is both sustainable and efficient.

This comprehensive understanding can help guide future policies and reforms in the healthcare sector, ensuring that the benefits of pharmaceutical advancements are accessible and efficiently managed for all members of society.

ALSO READ: Benefits of Insurance for Pharmaceutical Producers